Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 30, 1309-1311, May 1, 1970]
© 1970 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ertürk, E.
Right arrow Articles by Bryan, G. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ertürk, E.
Right arrow Articles by Bryan, G. T.

Urinary Bladder Carcinogenicity of N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide in Female Swiss Mice1

E. Ertürk, S. M. Cohen2 and George T. Bryan3

Division of Clinical Oncology, University of Wisconsin Medical School, Madison, Wisconsin 53706

N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide was fed to 50 female 5-week-old Swiss mice at a dose of 0.094% by weight of diet for 46 weeks, followed by 7 weeks of the control diet. Fifty-six mice received only the control diet. Thirty-three test mice survived 40 weeks or longer and had the following tumor incidences: urinary bladder, 31/33; generalized leukemia, 23/33; lung, 6/33; and 1 uterine tumor. In the controls, the following tumor incidences were found: generalized leukemia, 15/44; and lung, 1/44.

1 Supported in part by Grant CA-10017 from the National Cancer Institute, USPHS, and by a grant from the Wisconsin Division of the American Cancer Society.

2 Medical Scientist Trainee of the National Institute of General Medical Sciences, USPHS, GM-01932.

3 Career Development Awardee of the National Cancer Institute, USPHS, 1-K4-CA-8245-01A1.

Received 7/31/69. Accepted 11/20/69.




This article has been cited by other articles:


Home page
CarcinogenesisHome page
S. Sugiura, K. Ogawa, M. Hirose, F. Takeshita, M. Asamoto, and T. Shirai
Reversibility of proliferative lesions and induction of non-papillary tumors in rat urinary bladder treated with phenylethyl isothiocyanate
Carcinogenesis, March 1, 2003; 24(3): 547 - 553.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
K. Ogawa, M. St. John, M. L. De Oliveira, L. Arnold, T. Shirai, T.-T. Sun, and S. M. Cohen
Comparison of Uroplakin Expression During Urothelial Carcinogenesis Induced by N-Butyl-N-(4-Hydroxybutyl)Nitrosamine in Rats and Mice
Toxicol Pathol, November 1, 1999; 27(6): 645 - 651.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1970 by the American Association for Cancer Research.